Bisphosphonate News and Research

RSS

Bisphosphonate is a drug or substance used to treat hypercalcemia (abnormally high blood calcium) and bone pain caused by some types of cancer. Forms of bisphosphonates are also used to treat osteoporosis and for bone imaging. Bisphosphonates inhibit a type of bone cell that breaks down bone. Also called diphosphonate.

Genta Incorporated issued two key U.S. patents for gallium products franchise

Genta Incorporated has announced that two new patents related to the Company's franchise in gallium-containing products have issued in the United States.

8 Jan 2009

Oral bisphosphonates linked to increased jaw necrosis

Researchers at the University Of Southern California, School Of Dentistry release results of clinical data that links oral bisphosphonates to increased jaw necrosis

1 Jan 2009

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

New data released demonstrates that the addition of Zometa (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with early-stage disease.

14 Dec 2008

Breast and prostate cancer treatment may result in bone loss

A new cross-Canada study has found that breast and prostate cancer treatment can foster bone loss.

16 Nov 2008

Osteoporosis drugs may prevent future bone growth

Patients who start and eventually stop regimens of a common class of osteoporosis drugs called bisphosphonates may be unable to benefit from parathyroid hormone (PTH), which can rebuild bone mass lost due to advanced stage osteoporosis. PTH has been proven to increase the volume and strength of the honeycomb-like bone infrastructure, the inner mesh that begins to diminish in old age.

13 Nov 2008

Cheap drug combo stops breast cancer in its tracks

A drug 'combo' of chemotherapy and a treatment for brittle bones has a dramatic effect on breast cancer according to researchers in the UK.

13 Aug 2008

Alendronate may be associated with irregular heartbeat

Alendronate, a medication used to prevent fractures in women with osteoporosis, may be associated with an increased risk of atrial fibrillation, a type of abnormal heart rhythm, according to a report in the April 28 issue of Archives of Internal Medicine.

28 Apr 2008

Bisphosphonates - osteoporosis drugs triple risk of bone necrosis

A University of British Columbia and Vancouver Coastal Health Research Institute study has found that a popular class of osteoporosis drugs nearly triples the risk of developing bone necrosis, a condition that can lead to disfigurement and incapacitating pain.

16 Jan 2008

Effectiveness and risks of six bisphosphonates for osteoporosis

Many medications reduce the risk of bone fractures in people with osteoporosis, but the most commonly used drugs - bisphosphonates - have not been proven more effective than alternatives, according to a new report funded by the Agency for Healthcare Research and Quality (AHRQ), part of the U.S. Department of Health and Human Services.

18 Dec 2007

Early results show promise in reducing side effects from anastrozole

A common osteoporosis drug can shield women against the loss of bone mineral density - a side effect of the drug anastrozole which is taken to prevent breast cancer in the IBIS-2 study - according to new data presented at the San Antonio Breast Cancer Symposium.

14 Dec 2007

Major clinical trial of osteoporosis screening begins

Researchers are looking for local women in the Weston/North Somerset area over the age of 70 to take part in the second phase of a major clinical trial to find out if screening older women for osteoporosis can help to reduce the numbers who suffer bone fractures.

26 Nov 2007

Medical causes of iatrogenic renal disorders

Nephrologists and other health care providers need to be aware of certain medications and diagnostic test preparations that, in some patients, can cause damage to the kidneys, according to a special clinical update being presented at the American Society of Nephrology's 40th Annual Meeting and Scientific Exposition in San Francisco.

5 Nov 2007

$Once a year osteoporosis jab reduces fractures and saves lives$

Once a year osteoporosis jab reduces fractures and saves lives

A once a year injection of an osteoporosis drug has been found to reduce the number of new hip fractures for older people and also saves lives.

18 Sep 2007

$One in two women at high risk of bone fractures don't receive preventative treatment$

One in two women at high risk of bone fractures don't receive preventative treatment

One in two women at high risk of bone fractures don't receive preventative treatment, according to new research presented at the British Pharmaceutical Conference (BPC) in Manchester.

11 Sep 2007

Once a year treatment for osteoporosis now available in the U.S.

A once-a-year treatment for the bone-thinning disease osteoporosis has been given approval by the Food and Drug Administration (FDA) in the United States.

20 Aug 2007

Osteoporosis screening and treatment may be cost-effective for selected older men

It may be cost-effective to screen and treat selected older men with osteoporosis, depending on their age and if they have had a prior fracture, according to a study in the August 8 issue of JAMA: The Journal of the American Medical Association.

8 Aug 2007

Genta and Emisphere Technologies file investigational new drug exemption

Genta Inc. and Emisphere Technologies, Inc. have jointly announced the submission of an Investigational New Drug Exemption (IND) to the Endocrinologic and Metabolic Drugs Division of the U.S. Food and Drug Administration (FDA) for a new drug known as G4544.

2 Aug 2007

Intravenous bisphosphonates drugs increase odds of jaw or face-bone disease

Treatment with intravenous bisphosphonates drugs used to reduce harm done to bones by cancer or cancer therapy increases the risk of jaw or facial bone disease or infection, a large-scale comparative study by researchers at the University of Texas Medical Branch at Galveston (UTMB) has found.

27 Jun 2007

$Treatment with zoledronic acid effective in reducing fractures in women with postmenopausal osteoporosis$

Treatment with zoledronic acid effective in reducing fractures in women with postmenopausal osteoporosis

A treatment for osteoporosis delivered once a year is as effective as current monthly or weekly osteoporosis regimens at reducing the incidence of bone fractures, according to a new study led by a UCSF research team.

4 May 2007

FDA approves new Actonel dose

The U.S. Food and Drug Administration (FDA) approved a new dose for Actonel (risedronate sodium tablets) that will give patients the option of taking one Actonel 75 mg tablet on two consecutive days, for a total of two tablets monthly, to treat and prevent their postmenopausal osteoporosis.

18 Apr 2007